Headache, Migraine, Tension Headache, Occipital Neuralgia
Conditions
Keywords
headache, bupivicaine, cervical injection, paraspinous injection
Brief summary
Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.
Interventions
bilateral cervical injections of 0.5% bupivacaine into the paraspinous muscle at the c6-7 location for headache treatment
physicians choice of IV medications in treatment of headache
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient has to be able to provide own consent * English-speaking only * Non traumatic headache with VAS pain score of 5 or above out of 10
Exclusion criteria
* traumatic headache * Confused patients * allergy to bupivacaine * infection over injection site * recent neck surgery * hemodynamically unstable * bleeding disorder * anticoagulation use * pregnant, lactating women * prisoners
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual analog scale pain score 0-10 | 24 hours | Pain score at 30 minutes and 24 hours after treatment. 0 being no pain and 10 being the worse pain possible. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Emergency department length of stay | 24 hours | Duration that patients stayed in the Emergency department for |
| Need for additional medications | 24 hours | Whether an additional medication was given to patients after 30 minutes |
Countries
United States